374 related articles for article (PubMed ID: 31276525)
1. Sickle cell disease complications: Prevalence and resource utilization.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
[TBL] [Abstract][Full Text] [Related]
2. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
4. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
[TBL] [Abstract][Full Text] [Related]
5. An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization.
Binding A; Ward R; Phua C; Naessens V; O'Brien T; Bhatia S; Baranek H; Marani H; Mukerji G
CJEM; 2019 Jan; 21(1):55-62. PubMed ID: 29039292
[TBL] [Abstract][Full Text] [Related]
6. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
[TBL] [Abstract][Full Text] [Related]
8. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
[No Abstract] [Full Text] [Related]
9. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes.
Bou-Maroun LM; Meta F; Hanba CJ; Campbell AD; Yanik GA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28801954
[TBL] [Abstract][Full Text] [Related]
10. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
[TBL] [Abstract][Full Text] [Related]
11. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
Zaidi AU; Glaros AK; Lee S; Wang T; Bhojwani R; Morris E; Donohue B; Paulose J; Iorga ŞR; Nellesen D
Orphanet J Rare Dis; 2021 Nov; 16(1):460. PubMed ID: 34727959
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
[TBL] [Abstract][Full Text] [Related]
13. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
Kanter J; Bhor M; Li X; Li FY; Paulose J
J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
[TBL] [Abstract][Full Text] [Related]
14. Score Predicting Acute Chest Syndrome During Vaso-occlusive Crises in Adult Sickle-cell Disease Patients.
Bartolucci P; Habibi A; Khellaf M; Roudot-Thoraval F; Melica G; Lascaux AS; Moutereau S; Loric S; Wagner-Ballon O; Berkenou J; Santin A; Michel M; Renaud B; Lévy Y; Galactéros F; Godeau B
EBioMedicine; 2016 Aug; 10():305-11. PubMed ID: 27412264
[TBL] [Abstract][Full Text] [Related]
15. Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).
Elshazly SA; Heiba NM; Abdelmageed WM
Hematology; 2014 Jan; 19(1):52-9. PubMed ID: 23735470
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.
Cieri-Hutcherson NE; Hutcherson TC; Conway-Habes EE; Burns BN; White NA
Pharmacotherapy; 2019 Nov; 39(11):1095-1104. PubMed ID: 31505045
[TBL] [Abstract][Full Text] [Related]
17. Increased Patient Activation Is Associated with Fewer Emergency Room Visits and Hospitalizations for Pain in Adults with Sickle Cell Disease.
Cronin RM; Dorner TL; Utrankar A; Allen W; Rodeghier M; Kassim AA; Jackson GP; DeBaun MR
Pain Med; 2019 Aug; 20(8):1464-1471. PubMed ID: 30329108
[TBL] [Abstract][Full Text] [Related]
18. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome.
Buchanan ID; Woodward M; Reed GW
Pediatr Blood Cancer; 2005 Oct; 45(5):716-24. PubMed ID: 15926170
[TBL] [Abstract][Full Text] [Related]
19. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
Lobo C; Moura P; Fidlarczyk D; Duran J; Barbosa R; Oliveira T; do Nascimento EM; Bhakta N; Hankins JS
BMC Health Serv Res; 2022 Jan; 22(1):42. PubMed ID: 34998394
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis.
Shah SP; Twilla JD; Kemp L; Phelps GL; Reaves A
J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):201-207. PubMed ID: 30896312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
